Table 3. PET/CT-based and pleural parameters of NSCLC patients with first-onset MPE.
| Parameters | Actionable mutation (+) (n=58) | Actionable mutation (−) (n=45) | Total (n=103) |
|---|---|---|---|
| Qualitative parameters | |||
| Primary lesion adjacent to pleura (yes/no) | 24 (41.4)/34 (58.6) | 14 (31.1)/31 (68.9) | 38 (36.9)/65 (63.1) |
| Pleural FDG uptake (positive/negative) | 44 (75.9)/14 (24.1) | 33 (73.3)/12 (26.7) | 77 (74.8)/26 (25.2) |
| Intrathoracic lymph nodes FDG uptake (positive/negative) | 45 (77.6)/13 (22.4) | 35 (77.8)/10 (22.2) | 80 (77.7)/23 (22.3) |
| Pleural FDG uptake pattern | |||
| Pleural FDG uptake (−) | 14 (24.1) | 12 (26.7) | 26 (25.2) |
| Encasement | 4 (6.9) | 4 (8.9) | 8 (7.8) |
| Nodular | 37 (63.8) | 24 (53.3) | 61 (59.2) |
| Linear | 23 (39.7) | 19 (42.2) | 42 (40.8) |
| Quantitative parameters | |||
| LN SUVmax (g/mL) | 5.74 [3.72–9.41] | 6.38 [3.80–8.82] | 6.38 [3.80–8.82] |
| N1 SUVmax (g/mL) | 4.44 [2.81–7.07] | 4.29 [2.58–7.31] | 4.29 [2.58–7.31] |
| N2 SUVmax (g/mL) | 4.87 [3.05–8.69] | 4.79 [3.50–7.46] | 4.79 [3.50–7.46] |
| N3 SUVmax (g/mL) | 3.27 [1.78–5.00] | 2.84 [1.92–5.54] | 2.84 [1.92–5.54] |
| Pleural SUVmax (g/mL) | 5.14 [3.13–8.61] | 4.97 [3.20–7.91] | 4.97 [3.20–7.91] |
| Pleural MTV (mL) | 6.76 [0.00–27.60] | 13.52 [0.00–38.19] | 7.89 [0.00–30.41] |
| Pleural TLG (g) | 21.20 [0.00–79.86] | 30.32 [0.00–112.78] | 21.20 [0.00–91.99] |
| Primary SUVmax (g/mL) | 10.93 [6.88–13.72] | 9.53 [6.71–11.34] | 9.53 [6.71–11.34] |
| Pleural fluid parameters | |||
| p-CEA (μg/L) | 139.80 [22.59–709.98] | 11.69 [3.57–236.96] | 93.70 [4.22–528.92] |
| p-LDH (U/L) | 441.00 [258.50–723.80] | 287.00 [196.20–522.50] | 355.00 [225.00–673.80] |
| p-Glucose (mmol/L) | 6.20 [5.18–7.65] | 6.30 [4.90–7.90] | 6.20 [5.00–7.90] |
Data are presented as median [interquartile range] or n (%). PET/CT, positron emission tomography/computed tomography; NSCLC, non-small cell lung cancer; MPE, malignant pleural effusion; FDG, 18F-fluorodeoxyglucose; LN, lymph nodes; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; p-CEA, pleural fluid carcinoma embryonic antigen; p-LDH, pleural fluid lactate dehydrogenase.